Kineta Inc - KA STOCK NEWS

IMPACT

SENTIMENT

10/17/2023 08:30 AM

KA : Nasdaq

Kineta Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

IMPACT

SENTIMENT

10/12/2023 10:19 AM

KA : Nasdaq

Kineta Announces KVA12123 and Anti-CD27 Agonist Antibody Abstracts Accepted for Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023

IMPACT

SENTIMENT

10/09/2023 12:10 PM

KA : Nasdaq

Kineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023

IMPACT

SENTIMENT

10/05/2023 04:09 PM

KA : Nasdaq

Kineta, Inc. Announces Closing of $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

IMPACT

SENTIMENT

10/04/2023 08:30 AM

KA : Nasdaq

Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy

IMPACT

SENTIMENT

10/04/2023 08:00 AM

KA : Nasdaq

Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

IMPACT

SENTIMENT

10/03/2023 08:30 AM

KA : Nasdaq

Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial

IMPACT

SENTIMENT

09/28/2023 09:30 AM

KA : Nasdaq

Kineta Announces Participation at October Investor Conferences

IMPACT

SENTIMENT

09/25/2023 09:30 AM

KA : Nasdaq

Kineta to Present New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy

IMPACT

SENTIMENT

09/18/2023 09:30 AM

KA : Nasdaq

Kineta Announces New Research Agreement to Evaluate VISTA Biomarker Expression

Kineta Inc

Nasdaq:KA

KA Stock Data

Industry Pharmaceutical Preparation Manufacturing

Sector Manufacturing

Website Link

About KA

proteostasis therapeutics is discovering and developing novel small molecule therapeutics designed to control the body’s protein homeostasis, or proteostasis network. the proteostasis network maintains the body’s natural balance of proteins to protect us from numerous diseases. these novel therapies, or proteostasis regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the proteostasis network, such as alzheimer’s disease, emphysema, huntington’s disease, and type ii diabetes.